UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

Leukemia, 2017-06, Vol.31 (6), p.1340-1347

2017

Volltextzugriff (PDF)

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

Leukemia, 2014-11, Vol.28 (11), p.2188-2196

2014

Volltextzugriff (PDF)

Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

Leukemia, 2014-10, Vol.28 (10), p.2049-2059

2014

Volltextzugriff (PDF)

Modeling tumor–host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy

Leukemia, 2013-12, Vol.27 (12), p.2311-2321

2013

Volltextzugriff (PDF)

Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia

Leukemia, 2017-02, Vol.31 (2), p.340-349

2017

Volltextzugriff (PDF)

Proof of concept of NX‐2127, a first‐in‐class Bruton's Tyrosine Kinase (BTK) dual‐targeted protein degrader with immunomodulatory activity, in patients with DLBCL

Hematological oncology, 2023-06, Vol.41 (S2), p.570-571

2023

Volltextzugriff (PDF)

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia

Haematologica (Roma), 2015-12, Vol.100 (12), p.1495-1507

Wiestner, Adrian

2015

Volltextzugriff (PDF)

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

Blood, 2003-06, Vol.101 (12), p.4944-4951

2003

Volltextzugriff (PDF)

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia

Leukemia, 2013-08, Vol.27 (8), p.1769-1773

2013

Volltextzugriff (PDF)

P1303: POTENTIATING ANTI‐CD20 MONOCLONAL ANTIBODY THERAPY BY TARGETING COMPLEMENT C3 ACTIVATION FRAGMENTS COVALENTLY DEPOSITED ON LYMPHOMA CELLS

HemaSphere, 2022-06, Vol.6 (Suppl), p.1188-1189

2022

Volltextzugriff (PDF)

Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies

Leukemia, 2013-09, Vol.27 (9), p.1920-1923

2013

Volltextzugriff (PDF)

Chronic Lymphocytic Leukemia: Moving Forward—Rapidly

Seminars in hematology, 2014-07, Vol.51 (3), p.157-157

2014

Volltextzugriff (PDF)

Defective STAT signaling by the leptin receptor in diabetic mice

Proceedings of the National Academy of Sciences - PNAS, 1996-06, Vol.93 (13), p.6231-6235

1996

Volltextzugriff (PDF)

P649: A FIRST‐IN‐HUMAN PHASE 1 TRIAL OF NX‐2127, A FIRST‐IN‐CLASS ORAL BTK DEGRADER WITH IMID‐LIKE ACTIVITY, IN PATIENTS WITH RELAPSED AND REFRACTORY B‐CELL MALIGNANCIES

HemaSphere, 2022-06, Vol.6, p.547-548

2022

Volltextzugriff (PDF)

ANTI‐TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B‐CELL NON‐HODGKIN LYMPHOMA

Hematological oncology, 2017-06, Vol.35 (S2), p.46-47

2017

Volltextzugriff (PDF)

Thrombopoietin in Thrombocytopenic Mice: Evidence Against Regulation at the mRNA Level and for a Direct Regulatory Role of Platelets

Blood, 1996-01, Vol.87 (2), p.567-573

1996

Volltextzugriff (PDF)

Rituximab for autoimmune haemophilia: a proposed treatment algorithm

Haemophilia : the official journal of the World Federation of Hemophilia, 2005-01, Vol.11 (1), p.13-19

2005

Volltextzugriff (PDF)

INSIDE‐OUT VLA‐4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB‐TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE

Hematological oncology, 2017-06, Vol.35 (S2), p.109-110

2017

Volltextzugriff (PDF)

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

Haematologica (Roma), 2015-12, Vol.100 (12), p.1571-1578

2015

Volltextzugriff (PDF)

A Gene Expression-Based Method to Diagnose Clinically Distinct Subgroups of Diffuse Large B Cell Lymphoma

Proceedings of the National Academy of Sciences - PNAS, 2003-08, Vol.100 (17), p.9991-9996

2003

Volltextzugriff (PDF)

Genetically identical twin transplantation for chronic lymphocytic leukemia

Leukemia, 2007-12, Vol.21 (12), p.2452-2455

2007

Volltextzugriff (PDF)

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

Haematologica (Roma), 2016-06, Vol.101 (6), p.e254-e258

2016

Volltextzugriff (PDF)

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

The Lancet (British edition), 2004-01, Vol.363 (9403), p.105-111

2004

Volltextzugriff (PDF)

Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Haematologica (Roma), 2016-03, Vol.101 (3), p.e124-e125

2016

Volltextzugriff (PDF)

Imatinib inhibits T-cell receptor–mediated T-cell proliferation and activation in a dose-dependent manner

Blood, 2005-03, Vol.105 (6), p.2473-2479

2005

Volltextzugriff (PDF)

1 – 25 von 473

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(444)
Mit Volltextzugriff
(414)

Publikationsform

Sprache

Englisch
(469)
Deutsch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(238)
Life Sciences & Biomedicine
(224)
Humans
(178)
Hematology
(105)
Animals
(80)
Female
(80)
Male
(79)
Oncology
(79)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(74)
Aged
(56)
Chronic Lymphocytic Leukemia
(54)
Middle Aged
(51)
Biological And Medical Sciences
(42)
Medical Sciences
(41)
Leukemia, Lymphocytic, Chronic, B-Cell - Genetics
(38)
Leukemia, Lymphocytic, Chronic, B-Cell - Pathology
(38)
Veterinary Sciences
(36)
Mutation
(35)
Adult
(34)
Hematologic And Hematopoietic Diseases
(34)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(168)
Clinical Cancer Research
(24)
Leukemia & Lymphoma
(20)
Cancer Research
(17)
British Journal Of Haematology
(13)
Equine Veterinary Journal
(13)
Haematologica
(13)
Leukemia & Lymphoma/leukemia And Lymphoma
(12)
The Journal Of Immunology
(12)
Clinical Lymphoma, Myeloma And Leukemia
(10)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

Modeling tumor–host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy

Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia

Proof of concept of NX‐2127, a first‐in‐class Bruton's Tyrosine Kinase (BTK) dual‐targeted protein degrader with immunomodulatory activity, in patients with DLBCL

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia

P1303: POTENTIATING ANTI‐CD20 MONOCLONAL ANTIBODY THERAPY BY TARGETING COMPLEMENT C3 ACTIVATION FRAGMENTS COVALENTLY DEPOSITED ON LYMPHOMA CELLS

Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies

Chronic Lymphocytic Leukemia: Moving Forward—Rapidly

Defective STAT signaling by the leptin receptor in diabetic mice

P649: A FIRST‐IN‐HUMAN PHASE 1 TRIAL OF NX‐2127, A FIRST‐IN‐CLASS ORAL BTK DEGRADER WITH IMID‐LIKE ACTIVITY, IN PATIENTS WITH RELAPSED AND REFRACTORY B‐CELL MALIGNANCIES

ANTI‐TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B‐CELL NON‐HODGKIN LYMPHOMA

Thrombopoietin in Thrombocytopenic Mice: Evidence Against Regulation at the mRNA Level and for a Direct Regulatory Role of Platelets

Rituximab for autoimmune haemophilia: a proposed treatment algorithm

INSIDE‐OUT VLA‐4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB‐TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

A Gene Expression-Based Method to Diagnose Clinically Distinct Subgroups of Diffuse Large B Cell Lymphoma

Genetically identical twin transplantation for chronic lymphocytic leukemia

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Imatinib inhibits T-cell receptor–mediated T-cell proliferation and activation in a dose-dependent manner

Suchergebnisse filtern